CROSS-LONG-TERM

NTR487 📎

Regimen

Experimental
neoadjuvant CROSS (carboplatin + paclitaxel + 41.4 Gy RT) + surgery
Control
surgery alone

Population

Clinically resectable locally advanced esophageal or GEJ cancer (T1N1M0 or T2-3N0-1M0), both SCC and adenocarcinoma, minimum 5-year follow-up

Key finding

Median OS 48.6 vs 24.0 mo (HR 0.68, P=0.003) at 7y median follow-up. SCC subgroup dramatic benefit (HR 0.48, mOS 81.6 vs 21.1 mo); AC benefit also significant (HR 0.73).

Source: PMID 26254683

Timeline

    Guideline citations

    • NCCN ESOPHAGEAL (p.149)